Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Pharmaceuticals

Real-time Estimate Cboe Europe 04:21:59 2024-04-18 am EDT 5-day change 1st Jan Change
99.82 SEK -1.07% Intraday chart for Calliditas Therapeutics AB -7.88% -20.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires CI
Calliditas Therapeutics Gets US Patent Allowance for Cancer Treatment Inhibitor MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® CI
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
Calliditas Therapeutics Gets US FDA Orphan Drug Exclusivity for Kidney Disease Drug MT
Calliditas Therapeutics Says Kidney Disease Drug Granted Seven-Year Exclusivity Period by FDA MT
Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
Travere drug for rare kidney condition recommended for EU approval RE
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Chart Calliditas Therapeutics AB
More charts
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
100.9 SEK
Average target price
208 SEK
Spread / Average Target
+106.14%
Consensus
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. News Calliditas Therapeutics AB
  5. European Equities Traded in the US as American Depositary Receipts Falling Thursday